TESARO Inc (TSRO) was Resumed by Lake Street to “Buy” and the brokerage firm has set the Price Target at $114. Lake Street advised their investors in a research report released on Sep 6, 2016.
Many Wall Street Analysts have commented on TESARO Inc. BofA/Merrill Initiated TESARO Inc on Aug 30, 2016 to “Neutral”, Price Target of the shares are set at $97.RBC Capital Mkts Initiated TESARO Inc on Aug 12, 2016 to “Outperform”, Price Target of the shares are set at $122.Company shares were Reiterated by Mizuho on Aug 5, 2016 to “Buy”, Firm has raised the Price Target to $ 100 from a previous price target of $94 .
On the company’s financial health, TESARO Inc reported $-1.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.42 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.70. The company had revenue of $36.60 million for the quarter, compared to analysts expectations of $2.48 million. During the same quarter in the previous year, the company posted $-1.51 EPS.
TESARO Inc closed down -0.34 points or -0.40% at $84.35 with 4,63,213 shares getting traded on Thursday. Post opening the session at $85.14, the shares hit an intraday low of $83.26 and an intraday high of $85.5599 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on Sep 1, 2016, Jeffrey H. Hanke (Executive VP, R&D and CSO) sold 29,166 shares at $86.04 per share price. According to the SEC, on Jun 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $41.21 per share price. On Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price, according to the Form-4 filing with the securities and exchange commission.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.